NCT06407947View on ClinicalTrials.gov

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 6, 2024

Primary Completion Date

June 3, 2027

Study Completion Date

June 3, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Chimeric antigen receptor modified T cells Infusion

chimeric antigen receptor T cells

Trial Locations (1)

200000

RECRUITING

Juan Du, Shanghai

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Shanghai Changzheng Hospital

OTHER